Bicara Therapeutics Inc. Common Stock (BCAX)
Bicara Therapeutics Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $24.96, up 5.07% on the session, giving a market capitalisation of $1.64B. On trailing twelve-month figures it carries a trailing P/E of -8.05, a net margin of 0.0%. Its beta of -0.75 implies it has historically moved less than the broad market.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Bicara Therapeutics Inc. Common Stock is most often compared with the following Healthcare names: